We further found that RET silencing using RET-specific siRNAs significantly inhibited the growth of MCF7-derived ER+ breast cancer cells resistant to combined CDK4/6i and endocrine therapy (MPF-R) but not of T47D-derived double-resistant cell line (TPF-R). Here, RET is linked to breast carcinoma.